1 – 16 of 16
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Genome-wide investigation of persistence with methotrexate treatment in early rheumatoid arthritis
(
- Contribution to journal › Article
- 2023
-
Mark
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice : Results from the ARTIS programme
(
- Contribution to journal › Article
- 2022
-
Mark
Complement C4 copy number variation is linked to SSA/Ro and SSB/La autoantibodies in systemic inflammatory autoimmune diseases
(
- Contribution to journal › Article
-
Mark
Genome-wide association study identifies Sjögren's risk loci with functional implications in immune and glandular cells
(
- Contribution to journal › Article
- 2021
-
Mark
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population : A nationwide Swedish cohort study
(
- Contribution to journal › Article
-
Mark
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden : From infection severity to impact on care provision
(
- Contribution to journal › Article
-
Mark
Genetic and clinical basis for two distinct subtypes of primary Sjögren's syndrome
(
- Contribution to journal › Article
- 2020
-
Mark
Increased risk of multiple myeloma in primary Sjögren's syndrome is limited to individuals with Ro/SSA and La/SSB autoantibodies
(
- Contribution to journal › Letter
-
Mark
Active conventional treatment and three different biological treatments in early rheumatoid arthritis : Phase IV investigator initiated, randomised, observer blinded clinical trial
(
- Contribution to journal › Article
- 2017
-
Mark
Long-term follow-up in primary Sjögren's syndrome reveals differences in clinical presentation between female and male patients
(
- Contribution to journal › Article
- 2016
-
Mark
Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis
2016) In Annals of the Rheumatic Diseases(
- Contribution to journal › Article
- 2011
-
Mark
Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome
(
- Contribution to journal › Article
-
Mark
Ten years with biologics: to whom do data on effectiveness and safety apply?
(
- Contribution to journal › Article
- 2009
-
Mark
Cancer Risk in Patients With Rheumatoid Arthritis Treated With Anti-Tumor Necrosis Factor alpha Therapies Does the Risk Change With the Time Since Start of Treatment?
(
- Contribution to journal › Article
- 2008
-
Mark
The Swedish biologics register (ARTIS): observations of adverse events when using biologics in clinical practice
(
- Contribution to journal › Published meeting abstract
- 2007
-
Mark
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
(
- Contribution to journal › Article